Sunshine Biopharma (SBFM) has released an update.
Sunshine Biopharma has reported a significant increase in their 2024 second-quarter revenues, with a 67% rise compared to the same period last year, and a 61% increase in year-to-date revenues. Furthermore, the company has decreased its net loss by 45% for the quarter and 32% for the first half of the year, showcasing substantial financial improvement and effective management strategies.
For further insights into SBFM stock, check out TipRanks’ Stock Analysis page.